MT-0169

DRUG2 trials

Sponsors

Molecular Templates, Inc., M.D. Anderson Cancer Center

Conditions

LeukemiaRelapsed and/or Refractory Multiple Myeloma

Phase 1

A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

TerminatedNCT04017130

Molecular Templates, Inc.Relapsed and/or Refractory Multiple Myeloma

Start: 2020-02-05End: 2023-12-13Updated: 2024-01-17

Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

WithdrawnNCT06522373

M.D. Anderson Cancer CenterLeukemia

Start: 2024-10-21End: 2024-10-21Updated: 2026-05-15

Related Papers

447 Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma

Regular and Young Investigator Award Abstracts2021-11-014 citations

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Blood2020-11-0413 citations

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Blood2019-11-137 citations